



## Federal Retail Pharmacy Program Updates

### Vaccine program updates

#### CDC endorses recommendation of Novavax as an option

On Tuesday the CDC endorsed the Advisory Committee on Immunization Practices' (ACIP) recommendation that the Novavax COVID-19 vaccine be used as an option for adults ages 18 years and older.

The Novavax COVID-19 vaccine is the first COVID-19 protein subunit vaccine recommended for use in the United States. Having multiple types of vaccines offers more options and flexibility for people receiving COVID-19 vaccines, as well as jurisdictions and vaccine providers.

How it works:

- Protein subunit vaccines contain harmless pieces (proteins) of the COVID-19 virus alongside another ingredient called an adjuvant that helps the immune system respond to the virus in the future if exposed.
- Vaccines using protein subunits have been used for more than 30 years in the United States, beginning with the first licensed hepatitis B vaccine. Other protein subunit vaccines used in the United States today include those to protect against influenza and acellular pertussis (whooping cough).

The Novavax COVID-19 vaccine's safety and effectiveness have been confirmed by clinical research and by the thousands of people who have already received it. As occurs for all vaccines—including all COVID-19 vaccines—safety monitoring will continue for the Novavax vaccine.

[Read the interim clinical considerations](#)

#### **Novavax**

Extremely limited supply at this time with no indication of when we might receive next allocation. Each order is for 100 doses and will need to cover both first and second dose for patients.

If you believe you will have demand for this vaccine, please email [COVIDVaccines@AmerisourceBergen.com](mailto:COVIDVaccines@AmerisourceBergen.com). We will only be able to provide to a limited number of locations at this time.

Read the CDC statement

## Boosters

CDC recommends everyone ages 6 months and older get vaccinated against COVID-19. Everyone 5 years and older should also get a COVID-19 booster, if eligible. To learn if and when you can get boosters to stay up to date with your COVID-19 vaccines, use [CDC's COVID-19 booster tool](#). *Please note that Novavax is not authorized for boosters at this time.*

## V-Safe reminder

The CDC has updated V-Safe. Please remind your patients about this important resource. [Click here](#) for V-safe print resources.

## Oral antivirals program updates

### Evusheld

The U.S. Food and Drug Administration has issued an EUA for the emergency use of the unapproved product EVUSHELD (tixagevimab co-packaged with cilgavimab), SARS-CoV-2 spike protein-directed attachment inhibitor, for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARSCoV-2 and
- Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
- For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

EVUSHELD may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized

under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., antinfectives).

EVUSHELD has been authorized by FDA for the emergency use described above. EVUSHELD is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19.

- Please place allocation requests through the ABCOrder portal
- Reporting on inventory and administrations is mandatory, as it is for all therapeutic products (minimum twice per week)
- Pharmacists **cannot** prescribe Evusheld

#### Resources

- [EUA letter](#)
- [FAQ for healthcare providers](#)
- [Fact Sheet for patients, parents, and caregivers](#)

## Therapeutics allocation requests available via ABC Order

Pharmacies participating in the FRPTP may now request COVID-19 therapeutics allocation through the ABC Order COVID portal, similar to how COVID19 vaccines are requested. Email requests for therapeutics shipments will no longer be accepted. If you do not request therapeutics allocation through the ABC Order COVID portal, therapeutics inventory will not be shipped to your pharmacy. Allocation requests placed before 12pm ET Wednesdays will be delivered to your pharmacy early the following week. Orders submitted after 12pm on Wednesdays won't be processed until the next cycle.

## Resources

### Updated Implementation and Allocation Guides

- [Therapeutics FAQ](#)
- [Therapeutics implementation guide](#)
- [Vaccine implementation guide](#)
- [Vaccine allocation guide](#)

## New to the oral antivirals program? Download these resources!

- [Implementation Guide](#)
- [FAQ](#)

## COVID-19 Treatment Marketing Materials

Let your patients know that you have COVID-19 treatments available at your pharmacy with new print and digital marketing materials. Visit the “Coronavirus” library in [Brand Central Station](#) and [SOCi](#) to access the materials.



## Surveys, reporting, reminders

### Survey: Partnering with Long-Term Care facilities

The CDC has asked if any pharmacies participating in FRPP are currently partnering with any Long-Term Care Facilities, or if they would be able to. Please take this [brief survey](#).

### Are you interested in dispensing COVID-19 antiviral therapies?

If you are currently enrolled in the vaccine program and are interested in participating in the antiviral program, please email the Elevate Enrollments team at [elevateenrollments@amerisourcebergen.com](mailto:elevateenrollments@amerisourcebergen.com).

*At this time, only pharmacies enrolled in the vaccine program may participate in the antiviral program.*

**Questions?** Continue to work with your Business Coach or Sales Executive or send questions to [COVIDVaccines@AmerisourceBergen.com](mailto:COVIDVaccines@AmerisourceBergen.com). Please include your pharmacy name and NCPDP on all communications. This information will help us expedite our response to you.

**AmerisourceBergen**



click